GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
GeneDx enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
GeneDx's enterprise value was $1.60B on Nov 10, 2026, against $4.72B a year earlier. Over the last 5 years it ranged from -$139.68M to $4.72B, with a median of $622.03M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 10, 2026 | $1.60B | -56.3% |
| 2025 | Dec 31, 2025 | $3.65B | +78.7% |
| 2024 | Dec 31, 2024 | $2.04B | – |
| 2023 | Dec 29, 2023 | -$36.89M | – |
| 2022 | Dec 30, 2022 | -$95.56M | – |
| 2021 | Jan 29, 2021 | -$139.68M | – |
| 2020 | Dec 31, 2020 | -$139.68M | – |
See a number that looks wrong?